Life Biosciences injects first glaucoma patient in aging reversal trial
David Sinclair's company targets eye disease with cell reprogramming therapy.
Life Biosciences, a biotech company co-founded by aging researcher David Sinclair, has dosed its first volunteer in a clinical trial for glaucoma. The experimental treatment is injected directly into the eyeball and aims to regenerate healthy optic nerves by 'reprogramming' cells to a younger state. Sinclair envisions expanding the technique to treat other age-related diseases and ultimately reverse aging itself.
This approach represents the latest buzz in the longevity field, which has cycled through different 'hallmarks of aging' over the years. Early excitement around telomere lengthening (e.g., BioViva's self-experimentation) gave way to senolytic drugs that clear 'zombie cells,' but Unity Biotechnology's trials failed and the company shuttered. Now reprogramming has attracted massive funding: Altos Labs launched with $3 billion from Yuri Milner and Jeff Bezos, Retro Biosciences (backed by Sam Altman with $180 million) recently hit a $1.8 billion valuation, and NewLimit is also pursuing the approach.
- Life Biosciences' first volunteer received an injection of reprogramming therapy into the eye for glaucoma.
- Cellular reprogramming uses Nobel Prize-winning factors to return cells to a younger state and has shown improved tissue healing and vision in mice.
- Altos Labs raised $3B, Retro Biosciences $180M from Sam Altman, and NewLimit also active in this space.
Why It Matters
If successful, reprogramming could reverse multiple age-related diseases and potentially extend healthy human lifespan significantly.